The few human efficacy trials conducted to date, in which TZDs were deployed as monotherapies in heavily-pretreated cancer patients, failed to demonstrate any objective clinical responses, causing many investigators to abandon this approach and casting uncertainty over the validity of PPARγ as a rational drug target [12–14]. Here, PPARG is linked to cancer.